Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 520
- Registration Number
- NCT00180973
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Primary Thrombocythaemia 1 Trial
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- University of Cambridge
- Target Recruit Count
- 1398
- Registration Number
- NCT00175838
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambs, United Kingdom
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT00154375
- Locations
- 🇩🇪
Novartis Investigative Site, Duelmen, Germany
Stroke With Transfusions Changing to Hydroxyurea
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT00122980
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Nemours Children's Clinic, Orlando, Florida, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 285
- Registration Number
- NCT00117572
- Locations
- 🇭🇷
University Hospital for Tumors Zagreb, Zagreb, Croatia
🇺🇸Joliet Oncology Hematology Associates, Joliet, Illinois, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004089
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
- Conditions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00003172
- Locations
- 🇺🇸
CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00002674
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Robert H. Lurie Cancer Center
- Registration Number
- NCT00004901
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004897
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.